5531-31-7

Usage

InChI:InChI=1/C10H21N/c1-10(2,11)8-9-6-4-3-5-7-9/h9H,3-8,11H2,1-2H3

Upstream product

• 5531-32-8 N-(1,1-Dimethyl-2-cyclohexylaethyl)-formamid 
• 5531-30-6 2-cyclohexyl-1,1-dimethyl ethanol 
• 1245617-81-5 2-chloro-N-(2-cyclohexyl-1,1-dimethyl-ethyl)-acetamide 
• 2550-36-9 Cyclohexylmethyl bromide 
• 34405-42-0 α-(1-amino-1-methylethyl)benzenemethanol 
• 461-78-9 Chlorphentermine 
• 122-09-8 Phentermin 

Downstream Products

• 1245618-02-3 2'-{(R)-1-[(R)-3-(2-cyclohexyl-1,1-dimethyl-ethylamino)-2-hydroxy-propoxy]-ethyl}-3-methyl-biphenyl-4-carboxylic acid methyl ester 
• 1265633-70-2 5-(4-chlorophenyl)-N-(1-cyclohexyl-2-methylpropan-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide 

Relevant academic research and scientific papers

Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based design

Previously reported pentapeptidic BACE1 inhibitors, designed using a substrate-based approach, were used as lead compounds for the further design of non-peptidic BACE1 inhibitors. Although these peptidic and non-peptidic inhibitors, with a hydroxymethylcarbonyl isostere as a substrate transition-state mimic, exhibited potent BACE1 inhibitory activities, their molecular-sizes appeared a little too big (molecular weight of >600 daltons) for developing practical anti-Alzheimer's disease drugs. To develop lower weight BACE1 inhibitors, a series of tripeptidic BACE1 inhibitors were devised using a design approach based on the conformation of a virtual inhibitor bound to the BACE1 active site, also called 'in-silico conformational structure-based design'. Although these tripeptidic BACE1 inhibitors contained some natural amino acid residues, they are expected to be useful as lead compounds for developing the next generation BACE1 inhibitors, due to their low molecular size and unique structural features compared with previously reported inhibitors.

1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists

The present invention is directed to novel 1,1 -(dimethyl-ethylamino)-2- hydroxy-propoxy]-ethyl}-3-methyl-biphenyl-4-carboxylic acid derivatives and pharmaceutically acceptable salts thereof of structural formula I wherein the variable R1 is as described herein. Also provided are pharmaceutical compositions comprising the compounds of formula I as well as methods of treatment employing compounds of formula I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget's disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy.